Skip to content
PIL Logo

Octreotide 50, 100, 200 and 500 micrograms/ml Solution for Injection

Last Updated on eMC 21-Apr-2015 View document  | Ranbaxy (UK) Limited a Sun Pharmaceutical Company Contact details

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC.  For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 21-Apr-2015 and displayed until Current

Reasons for adding or updating:

  • Change to section 2 - use in children/adolescents
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 2 - driving and using machines
  • Change to section 3 - how to take/use
  • Change to section 3 - overdose, missed or forgotten doses
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision
  • Change to information for healthcare professionals
  • Change to section 1 - what the product is used for
  • Change to section 2 - what you need to know - warnings and precautions

Updated on 23-Sep-2014 and displayed until 21-Apr-2015

Reasons for adding or updating:

  • Improved presentation of PIL

Updated on 04-Apr-2013 and displayed until 23-Sep-2014

Reasons for adding or updating:

  • Change to section 1 - what the product is used for
  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 2 - driving and using machines
  • Change to section 2 - excipient warnings
  • Change to section 3 - dose and frequency
  • Change to section 3 - how to take/use
  • Change to section 3 - overdose, missed or forgotten doses
  • Change to section 4 - possible side effects
  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - marketing authorisation holder

Updated on 19-Mar-2010 and displayed until 04-Apr-2013

Reasons for adding or updating:

  • Change to name of manufacturer
  • Change to MA holder contact details

Updated on 07-Jul-2008 and displayed until 19-Mar-2010

Reasons for adding or updating:

  • New PIL for eMC ie a PIL for an existing product but one that is new to the eMC

Company contact details

Ranbaxy (UK) Limited a Sun Pharmaceutical Company

Company image
Address

5th Floor, Hyde Park, Hayes, 3, 11 Millington Road, Hayes, UB3 4AZ, UK

E-mail
Medical Information e-mail
Telephone

+44 (0) 208 848 8688

Medical Information Direct Line

+44 (0) 208 848 8688

Out of Hours contact

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

octreotide acetate

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue